company background image
STRO

Sutro Biopharma NasdaqGM:STRO Stock Report

Last Price

US$7.10

Market Cap

US$408.1m

7D

-4.3%

1Y

-54.4%

Updated

04 Dec, 2022

Data

Company Financials +
STRO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

STRO Stock Overview

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company.

Sutro Biopharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sutro Biopharma
Historical stock prices
Current Share PriceUS$7.10
52 Week HighUS$16.60
52 Week LowUS$3.33
Beta1.0
1 Month Change-3.66%
3 Month Change23.26%
1 Year Change-54.37%
3 Year Change-29.77%
5 Year Changen/a
Change since IPO-53.29%

Recent News & Updates

Sutro Biopharma: Partnership Progress Warrants Exposure

Aug 16

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)

Aug 11
New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

May 02
Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?

Dec 26
Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?

Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts

May 09
Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts

Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

May 07
Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Jan 06
Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Shareholder Returns

STROUS BiotechsUS Market
7D-4.3%4.2%1.5%
1Y-54.4%-7.4%-14.9%

Return vs Industry: STRO underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: STRO underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is STRO's price volatile compared to industry and market?
STRO volatility
STRO Average Weekly Movement8.0%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: STRO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: STRO's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003259Bill Newellhttps://www.sutrobio.com

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+ The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.

Sutro Biopharma, Inc. Fundamentals Summary

How do Sutro Biopharma's earnings and revenue compare to its market cap?
STRO fundamental statistics
Market CapUS$408.08m
Earnings (TTM)-US$122.73m
Revenue (TTM)US$69.79m

5.8x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
STRO income statement (TTM)
RevenueUS$69.79m
Cost of RevenueUS$123.96m
Gross Profit-US$54.17m
Other ExpensesUS$68.57m
Earnings-US$122.73m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.14
Gross Margin-77.61%
Net Profit Margin-175.85%
Debt/Equity Ratio8.4%

How did STRO perform over the long term?

See historical performance and comparison